We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

By LabMedica International staff writers
Posted on 27 Jan 2022
Print article
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)
A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.

Genome sequencing allows scientists to see a patient's complete DNA makeup, which contains information about everything from eye color to inherited diseases. Genome sequencing is vital for diagnosing patients with diseases rooted in their DNA: Once doctors know the specific genetic mutation, they can tailor treatments accordingly.

An International team of scientists led by those at Stanford University (Stanford, CA, USA) enrolled and sequenced the genomes of 12 patients, five of whom received a genetic diagnosis from the sequencing information in about the time it takes to round out a day at the office. Traditional genome-sequencing techniques chop the genome into small bits, spell out the exact order of the DNA base pairs in each chunk, then piece the whole thing back together using a standard human genome as a reference.

Standard tests screen a patient's blood for markers associated with disease, but they only scan for a handful of well-documented genes. Commercial labs, which often run these tests, are slow to update the molecules for which they screen, meaning it can take a long time before newly discovered disease-causing mutations are integrated into the test, and that can lead to missed diagnoses. That is why rapid genome sequencing could be such a game-changer for patients ailing from rare genetic disease.

To achieve super-fast sequencing speeds, the scientists needed new hardware. So they contacted colleagues at Oxford Nanopore Technologies (Oxford Science Park, UK) who had built a machine composed of 48 sequencing units known as flow cells. The idea was to sequence just one person’s genome using all flow cells simultaneously. In one of the cases, it took a swift 5 hours and 2 minutes to sequence a patient's genome. The team's diagnostic rate, roughly 42%, is about 12% higher than the average rate for diagnosing mystery diseases.

Euan Ashley, MB ChB, DPhil, professor of medicine, of genetics and of biomedical data science and a senior author of the study, said, “A few weeks is what most clinicians call 'rapid' when it comes to sequencing a patient's genome and returning results. Mutations that occur over a large chunk of the genome are easier to detect using long-read sequencing. There are variants that would be almost impossible to detect without some kind of long-read approach. It's also much faster so that was one of the big reasons we went for this approach. That's why rapid genome sequencing could be such a game-changer for patients ailing from rare genetic disease.” The study was published on January 12, 2022 in the journal The New England Journal of Medicine.

Related Links:
Stanford University
Oxford Nanopore Technologies


Gold Supplier
Clinical Chemistry Reagents
SEKURE Clinical Chemistry Reagents
New
Microplate Washer
STAT FAX 2600
New
Homogenizer
DP0150 Pulse 150
New
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.